- Home
- NB vs TCRX Comparison
NB vs TCRX Comparison
Compare NB & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- TCRX
- Stock Information
- Founded
- NB 1987
- TCRX 2018
- Country
- NB United States
- TCRX United States
- Employees
- NB N/A
- TCRX N/A
- Industry
- NB Metal Mining
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NB Basic Materials
- TCRX Health Care
- Exchange
- NB Nasdaq
- TCRX Nasdaq
- Market Cap
- NB 116.9M
- TCRX 115.8M
- IPO Year
- NB N/A
- TCRX 2021
- Fundamental
- Price
- NB $2.23
- TCRX $2.17
- Analyst Decision
- NB Strong Buy
- TCRX Strong Buy
- Analyst Count
- NB 2
- TCRX 5
- Target Price
- NB $3.63
- TCRX $11.40
- AVG Volume (30 Days)
- NB 401.5K
- TCRX 373.5K
- Earning Date
- NB 03-04-2025
- TCRX 03-05-2025
- Dividend Yield
- NB N/A
- TCRX N/A
- EPS Growth
- NB N/A
- TCRX N/A
- EPS
- NB N/A
- TCRX N/A
- Revenue
- NB N/A
- TCRX $9,362,000.00
- Revenue This Year
- NB N/A
- TCRX N/A
- Revenue Next Year
- NB N/A
- TCRX $5.14
- P/E Ratio
- NB N/A
- TCRX N/A
- Revenue Growth
- NB N/A
- TCRX N/A
- 52 Week Low
- NB $1.27
- TCRX $1.99
- 52 Week High
- NB $4.00
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- NB 52.03
- TCRX 37.12
- Support Level
- NB $2.34
- TCRX $2.02
- Resistance Level
- NB $2.55
- TCRX $2.17
- Average True Range (ATR)
- NB 0.29
- TCRX 0.16
- MACD
- NB -0.05
- TCRX 0.02
- Stochastic Oscillator
- NB 18.82
- TCRX 26.47
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.